Annovis Bio Says Its Parkinson's Phase 3 Study Of Its Lead Compound Buntanetap Has Reached Full Enrollment In A Record Nine Months After It Began; The Study Is Expected To Conclude In November With Top-line Assessment Data Available By The End Of The Year
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio announced that its Phase 3 study of lead compound Buntanetap for Parkinson's disease has reached full enrollment in just nine months. The study is expected to conclude in November, with top-line assessment data available by the end of the year.
June 08, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's Phase 3 study of Buntanetap for Parkinson's has reached full enrollment, with results expected by the end of the year.
The news of Annovis Bio's Phase 3 study reaching full enrollment in a record time indicates strong progress in the development of their lead compound Buntanetap for Parkinson's disease. This positive development is likely to have a short-term positive impact on the company's stock price, as investors may see it as a sign of potential success in the study and future revenue generation from the drug if approved.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100